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ABSTRACT
INTRODUCTION: New prognostic systems have been proposed, aimed at improving the ability to predict 
survival and progression in myelodysplastic syndome (MDS) patients, as well as to select the accurate 
therapy. 
PURPOSE: The aim of this study was to determine the prognostic score for patients with MDS, diagnosed in 
the Hematology Clinic, University hospital, Varna, comparing different prognostic scoring systems.
MATERIALS AND METHODS: 92 patients with MDS, diagnosed between 2004 and 2012 were included in 
the study. The median age was 72 (20-91 years), 87% >60 years of age, 52 men and 41 women. The prognostic 
score was determined according to IPSS, WPSS, MDACSS. The parameters assessed were WHO type, karyo-
type, cytopenias, percentage of marrow blasts, age, performing status and transfusion dependence.
RESULTS: Cytogenetic studies were performed in 100% of patients.  Abnormalities were found in 34.8%, the 
most common-del-5q (14.6%),  -Y (4.5%), complex karyotype (8%), +8 (2.2%).  Patients were distributed ac-
cording to the cytogenetic risk -low-87.2%, intermediate-7.7%, high-5.1%. According to IPSS 41% of the pa-
tients were with low risk, 34%-Int-1, 16%-Int-2, high-9%.  WPSS distributed the patients in 5 groups: very 
low-11%, low risk-43%, int-21%, high-20%, very high-5%. According to MDACSS 14% of the patients were 
with low, 54%-Int-1, 18%-Int2, 13% with high risk. 
CONCLUSION: Significant correlation was found between the risk groups and AML transformation and sur-
vival. However, the comparison between the different scoring systems demonstrated the advantage of prog-
nostic systems, based on a broader range of clinical parameters in better distribution of intermediate risk 
patients and the precise determination of high and very high risk.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are 
clonal disorders of hematopoiesis characterised 
by ineffective hematopoiesis, peripheral blood 
cytopenias, and risk of progression to acute myeloid 
leukemia (AML). The clinical phenotype of patients 
with MDS is diverse with respect to the number and 
severity of cytopenias, cellularity and blast count in 
the bone marrow, rate of progression to AML, overall 
survival, and response to treatment. 
Staging systems are a key to accurate MDS 
diagnosis and selection of therapy. MDS staging and 
classification schemes have evolved significantly over 
the past few decades to address our understanding 
of the biology of this disease. A variety of clinical 
and morphological issues led to the development 
of a new MDS staging system by the World 
Health Organization (WHO) to further refine the 
classification criteria and improve the assignment of 
prognosis for intermediate-risk cases (3).
In the summer of 2008 a revised version of 
WHO syllabus was published (10). For the first time 
the 2008 WHO classification proposed a diagnosis of 
“presumptive MDS” in the case of persistent clinical 
cytopenias without dysplasia if certain cytogenetic 
abnormalities are present. The term Idiopathic 
cytopenia of undetermined significance (ICUS) is 
applied if the patients have persistent cytopenias 
without alternative explanation, no dysplasia and 
specific cytogenetic abnormalities. Refractory 
cytopenia with unilineage dysplasia (RCUD) includes 
cases where dysplasia is demonstrated in 10% of one 
cell line. The majority of cases with fibrosis are RAEB 
and are associated with a worse outcome. For CMML 
the diagnostic requirements remain the same. A 
subset of patients with CMML and eosinophilia, 
associated with genetic abnormalities including 
platelet derived growth factor receptor (PDGFR), 
are better classified as myeloid neoplasms with 
eosinophilia. Provisional entity refractory anemia 
with ringed sideroblasts associated with marked 
thrombocytosis (RARS-T) is proposed where up to 
60% of patients harbour the JAK2 V617F mutation. 
The term myeloproliferative disorders was replaced 
by myeloproliferative neoplasms.
Recently several novel prognostic systems have 
been proposed, aimed at improving the ability to 
predict survival and progression in MDS patients. 
The most widely used MDS prognostic system 
in clinical practice continues to be the International 
Prognostic Scoring System (IPSS) (4), but clinicians 
have recognised for many years that IPSS has a 
number of clinical limitations. These limitations 
include unsatisfactory applicability of IPSS to a variety 
of clinical situations such as secondary, therapy-
related MDS or previously treated patients; lack of 
sensitivity to the degree of patients‘ peripheral blood 
cytopenias, especially severe thrombocytopenia; 
excessive emphasis on elevated marrow blast 
proportion compared to high risk cytogenetics; 
a restricted number of included karyotypes; and 
failure to account for either comorbid conditions, or 
newer biomarkers of demonstrated prognostic value 
such as the high grade marrow fibrosis, or elevated 
serum ferritin level. Collectively these limitations 
made the original IPSS a less accurate and helpful 
tool and prompted other investigators to derive and 
propose newer risk stratification tools. Malcovati 
et al (8) developed a dynamic prognostic model 
based on the variables introduced by the WHO 
Classification-Based Prognostic Scoring System 
(WPSS). The WPSS score integrates the three most 
important prognostic factors in MDS patients 
classified according to WHO criteria: karyotype, 
WHO subgroup, and requirement for red blood cell 
(RBC) transfusion. This model provides dynamic 
prognostic information throughout the clinical 
course estimating the relationship between variables 
repeatedly measured during the follow-up.  The 
WPSS stratifies MDS patients into five different risk 
categories: very low, low, intermediate, high, or very 
high.  Significant differences are seen among the 
five groups in overall survival and risk of AML. In 
2008, Kantarjian and colleagues from MD Andersen 
Cancer Center (7) proposed a 4-strata generalised risk 
model for patients with MDS- MD Andersen Cancer 
Center risk model (MDACSS). MDACSS is both 
sensitive to the degree of cytopenias and emphasises 
the importance of high-risk karyotype, which as 
several analyses have suggested is a more powerful 
marker of a negative outcome than increased 
marrow blast proportion. A multivariate analysis of 
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prognostic factors in the study group identified the 
following adverse, independent factors as continuous 
and categorical values (P<.001): poor performance, 
older age, thrombocytopenia, anemia, increased 
bone marrow blasts, leukocytosis, chromosome 7 or 
complex (≥3) abnormalities, and prior transfusions. 
Cutoffs for anemia, thrombocytopenia and blasts, 
and cytogenetic subsets were different according to 
the IPSS. The new MDS prognostic model divided 
patients into 4 prognostic groups with significantly 
different outcomes. 
The cytogenetic profile in patients with MDS 
remains the most powerful independent prognostic 
marker. The cytogenetic risk is determined according 
to the IPSS criteria. Recently a much broader range 
of karyotypes than the initial IPSS (based on the 
German-Austrian consortium) was analysed and 
patients were distributed in 4 cytogenetic risk 
groups (6). Cytogenetic analyses in 2072 patients 
revealed clonal abnormalities in 52.3%. Karyotypes 
involving deletions of 5q were the most frequent, 
occurring in 30% of the patients with clonal 
cytogenetic abnormalities. Other frequent anomalies 
were −7/del(7q) (21%), +8 (16%), −18/18q− (7%), 
20q− (7%), −5 (6%), −Y (5%), −17/17p− (including 
isochromosome (17q)) (5%), +Mar (5%), +21 (4%), 
inv/t(3q) (4%), −13/13q− (4%), +1/+1q (3%), −21 (3%), 
+11 (3%), 12p− (2%), t(5q) (2%), 11q− (2%), and t(7q) 
(2%). For all World Health Organization (WHO) 
and French-American-British (FAB) classification 
system subtypes, the karyotype provided additional 
prognostic information.
All the advantages of the new scoring systems 
were incorporated in the revised IPSS (R-IPSS) 
first discussed in May 2011 by Greenberg at the 
11th MDS Foundation International Symposium 
in Edinburgh, Scotland and later published in 2012 
(5). The basic parameters of R-IPSS are the bone 
marrow cytogenetics, marrow blast percentage, and 
cytopenias. The novel components of the system 
included: 5 rather than 3 cytogenetic prognostic 
subgroups with specific and new classifications of 
a number of less common cytogenetic subsets (9), 
splitting the low marrow blast percentage value, and 
depth of cytopenias. This model defines 5 rather than 
the 4 major prognostic categories that are present in 
the IPSS. This system comprehensively integrated 
the numerous known clinical features into a method 
analysing MDS patient prognosis more precisely 
than the initial IPSS. 
A future direction in the development of new 
risk stratification systems is the incorporation 
of novel prognostic markers such as the somatic 
mutations found in MDS (1). The somatic gene 
mutations landscape continues to expand and none 
of the existing risk models incorporate additional 
analysis. Bejar et al (2) examined whether the 
mutation status for each gene was associated with 
clinical variables, including specific cytopenias, the 
proportion of blasts, and overall survival. They found 
that mutations in EZH2, ASHL2, TP53, RUNX1 all 
conferred an IPSS independent adverse prognosis in 
terms of overall survival. DNMT3A mutations are 
also associated with strikingly adverse negative IPSS 
and karyotype independent prognostic effect on 
both MDS and AML (11).
The aim of this study was to classify and 
determine the prognostic score for patients with 
MDS, diagnosed in the Hematology Clinic, 
University hospital, Varna, comparing different 
prognostic scoring systems.
PATIENTS AND METHODS
92 patients with MDS, diagnosed between 
2004 and 2012 were included in the study. The 
Fig. 1. Distribution of MDS patients according to WHO 
classification
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median age was 72 (20-91 years), 87% >60 years of 
age, 52 men and 41 women. The prognostic score 
was determined according to IPSS, WPSS, and 
MDACSS. The parameters assessed were WHO 
type, karyotype, cytopenias, percentage of marrow 
blasts (morphological reassessment), age, performing 
status, transfusion dependence.
RESULTS
Classification of MDS cases
Patients were classified according to WHO 
criteria.  The distribution of MDS subtypes is 
presented on Fig. 1: RA-29%, RCMD-27%, RARS-
5%, RAEBI-12%, RAEBII-11%, 5q syndrome-11%, 
MDS/MPS-2%, MDS/fibrosis 2%. 
Cytogenetic analysis
Cytogenetic study was performed in 100% of 
patients. Abnormalities were found in 34.8%, the 
most common-del-5q (14.6%), -Y (4.5%), complex 
karyotype (8%), +8 (2.2%). Cytogenetic risk groups 
were determined according to two different 
cytogenetic risk assessing scores-IPSS and Haase et 
al. Significant correlation was found between the 
cytogenetic risk groups and AML transformation 
and survival (Fig. 2).
Risk scoring 
Tree different prognostic scoring systems were 
used for the assessment of the risk groups of the 
MDS patients. According to IPSS 41% of the patients 
were with low risk, 34% with Int-1, 16%-Int-2%, 
high-9%. WPSS distributed the patients in 5 groups: 
Fig. 2. Cytogenetic abnormalities and cytogenetic risk groups-correlation with survival and AML transformation
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very low-11 %, low risk-43%, int-21%, high-20%, very 
high-5%. According to MDACSS 14% of patients 
were with low, 54%-Int-1, 18%-Int2, 13%-high risk. 
Significant correlation was found between the risk 
groups and AML transformation and survival in all 
risk stratification systems (Fig. 3)
DISCUSSION
In the present study we applied different 
prognostic scoring systems for risk assessment in 
MDS using morphological, cytogenetic, laboratory 
and clinical parameters. The cytogenetic risk group 
appeared as a very powerful prognostic factor; the risk 
of transformation in AML correlates significantly 
with the risk group. The cytogenetic prognostic 
system proposed by Haase et al. determines the high 
risk group more precisely since all patients in this 
group have AML progression compared to 44% in 
IPSS high risk group. 
Fig. 3. MDS risk groups according to IPSS, WPSS, MDACSS- correlation with survival and AML transformation
The three prognostic scoring systems used in 
this study distribute the patients in risk groups with 
significant difference in survival and AML transfor-
mation. However, comparison between the differ-
ent scoring systems demonstrated the advantage of 
prognostic systems as WPSS and MDACSS, based on 
broader range of clinical parameters, in better dis-
tribution of intermediate risk patients and the pre-
cise determination of high and very high risk (Fig. 4).
The accurate diagnosis and risk stratification 
in MDS is a key to the selection of therapy, as well 
as to predict survival and progression in AML. 
Incorporation of novel prognostic markers will 
continue to require revision of the existing risk 
stratification systems.
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Fig. 4. Comparison between the different scoring systems-IPSS, WPSS, MDACSS
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